Literature DB >> 9774390

Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif.

C H Chan1, J Wang, R R French, M J Glennie.   

Abstract

CD22 is a key receptor on B-lymphocytes that modulates signaling during antigenic stimulation. We have defined a novel cytoplasmic motif in human CD22 that controls its unusually rapid turnover at the plasma membrane. Chimeric and mutated CD22alpha cDNA vectors were constructed and stably transfected in CD22-negative Jurkat T-lymphocytic cells. Two assays were employed to measure CD22alpha internalization: first, cytoplasmic uptake of radioiodinated anti-CD22 monoclonal antibody; and second, lethal targeting of a toxin, saporin, into cells via CD22 using bispecific F(ab')2 ([anti-CD22 x anti-saporin]) antibody. Results showed that CD22alpha lacking a cytoplasmic tail was not internalized and that replacement of the cytoplasmic tail of CD19 with that of CD22alpha resulted in a chimeric molecule that behaved like CD22alpha and internalized rapidly. Step-wise deletion of the cytoplasmic tail of CD22alpha located the internalization motif to a polar region of 11 residues (QRRWKRTQSQQ) proximal to the plasma membrane, a part of the molecule predicted to form a coil or turn structure. Interestingly, additional CD22 mutants showed that the two glutamine residues sandwiching the serine are critical to internalization but that the serine itself is not.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774390     DOI: 10.1074/jbc.273.43.27809

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

2.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

3.  Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Authors:  Veronika Bachanova; Arthur E Frankel; Qing Cao; Dixie Lewis; Bartosz Grzywacz; Michael R Verneris; Celalettin Ustun; Aleksandr Lazaryan; Brian McClune; Erica D Warlick; Hagop Kantarjian; Daniel J Weisdorf; Jeffrey S Miller; Daniel A Vallera
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

4.  Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages.

Authors:  Peter L Delputte; Hanne Van Gorp; Herman W Favoreel; Inge Hoebeke; Iris Delrue; Hannah Dewerchin; Frank Verdonck; Bruno Verhasselt; Eric Cox; Hans J Nauwynck
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

5.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

6.  Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22.

Authors:  Julia Jellusova; Lars Nitschke
Journal:  Front Immunol       Date:  2012-01-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.